Patent ID: 9359439
Filing Date: 2016-06-07
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method for treatment of cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of antibody composition comprising a chimeric or humanized anti-EGFR antibody or fragment or derivative thereof, comprising a heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2 and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO: 4, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 5and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 6; wherein the antibody comprises the following characteristics: (i) the antibody comprises a glycosylation site present in the Fc part; (ii) in the composition at least 70% of the carbohydrates attached to the Fc part do not carry a fucose residue; (iii) in the composition at least 70% of the carbohydrates attached to the Fc part do not carry a sialic acid residue; (iv) in the composition at least 5% of the carbohydrates attached to the Fc part carry a bisecting acetylglucosamine residue; (v) in the composition at least 60% of the carbohydrates attached to the antibody carry at least one galactose residue; (vi) the carbohydrates attached to the antibody do not comprise a Galili epitope having the structure Galα(1→3)Galβ(1→4)GlcNAc; and (vii) the carbohydrates attached to the antibody do not comprise N-glycolylneuraminic acid (NeuGc) residues; (viii) optionally, in the composition at least 50% of the carbohydrates attached to the Fab part of the antibody or fragment or derivative thereof carry bisGlcNAc, wherein the patient is treated after failure of cetuximab treatment.